Cannabis Schedule III: Seven Manufacturer Pain Points the April 2026 Order Created

By Andrew Samann · Cofounder, Intrepid Scientific · 2026-06-01

The April 2026 cannabis rescheduling — AG Order 6754-2026, published in the Federal Register on April 28 — created a partial Schedule III regime for FDA-approved drug products containing marijuana and for state-medical marijuana operating under qualifying state licenses. Within ~72 hours of the order taking effect, a recognizable pattern emerged in the inbound calls from manufacturers, MSOs, and their counsel: the same seven operational pains, varying only in priority and severity.

This piece names those seven pains in the order they typically present, frames why each one is hard for a state-cannabis operator who hasn't done federal pharma work before, and points to the companion pieces in the Intrepid Insights series that address each one in depth. It is diagnostic, not prescriptive — meant to help leadership orient before contracting consulting work, not to substitute for that work.

For the underlying regulatory architecture and timeline, see the companion piece The Pharmaceutical Era: A Strategic Roadmap for Cannabis Manufacturing After Rescheduling. For the step-by-step DEA registration workbook, see the free 60-Day Federal Pathway Primer.

What changed, in three sentences

On April 28, 2026, FDA-approved drug products containing marijuana and marijuana subject to qualifying state medical licenses moved from Schedule I to Schedule III of the Controlled Substances Act. State-medical operators now have access to a new expedited DEA registration pathway (21 CFR § 1301.13(k)) with a 60-day filing window that closes on or about June 27, 2026. Everything that wasn't explicitly rescheduled — adult-use marijuana, bulk unlicensed marijuana, synthetically derived THC — remains Schedule I.

The seven pains below all flow from that bifurcation. Some are sprint-shaped (60-day or 180-day clocks). Others are positioning bets (do you want EU export? IND/NDA pathway? Pharma partnership?). All seven require explicit operational decisions in the next two quarters.

Pain Point #1 — DEA Form 225 / Form 224 Filing Readiness

The June 27 deadline is the immediate one. State medical licensees who file by then keep operating under their state license during DEA review (and DEA has committed to a six-month decision target for in-window filings). Operators who miss the window cannot lawfully cultivate, manufacture, or process under federal law until DEA grants the registration.

The application itself is straightforward in form and challenging in substance:

Form 225 for manufacturers and distributors; Form 224 for dispensers.
A vertically integrated entity can stack registration types under § 1301.13(k)(1)(E), but federal scope cannot exceed state scope.
Annual fees per the current schedule: Manufacturer $3,699; Distributor $1,850; Dispenser $888 for a 3-year registration. The medical-marijuana dispensary application carries a separate $794 annual application fee per the DEA Diversion Control portal.
The three new Schedule III drug codes that the rescheduling created — 7362 (marijuana in an FDA-approved or state-medical-licensed product), 7353 (marijuana extract in same), 7386 (naturally derived Δ9-THC in same). Note: the older codes 7350 (marijuana) and 7360 (extract) remain in Schedule I for unlicensed bulk material. Operators who select the wrong codes invite RFIs and delays.
A cultivation manufacturer registration must specify the areas in which cultivation is permitted (§ 1301.13(k)(6)(C)). This means legal descriptions or parcel/APN numbers for every grow location — indoor cultivation rooms, greenhouses, outdoor parcels, tissue-culture labs, mother and clone rooms, drying and curing rooms.

The pain here is rarely the form. It is the document assembly required to support a clean filing — ownership and disclosure history, liability disclosures, state-license documentation per location, cultivation-area parcel mapping, security plan, supplier and downstream-partner DEA numbers, twelve SOPs (ordering, receiving, inventory, storage, security, dispensing, distribution, destruction, theft/loss, due diligence, corresponding responsibility, recordkeeping), and a written Public-Interest defense memo addressing the § 823(e)–(g) factors.

See the 60-Day Federal Pathway Primer for the complete pre-submission checklist, document pack, and Public-Interest defense framework.

Pain Point #2 — The Public-Interest Diversion-Control Defense

Section 1301.13(k) creates a presumption in favor of registration — the Administrator "shall register" applicants under this subsection — but it is rebuttable, and the rule's commentary signals DEA will exercise its discretion to deny where the underlying state regulatory file is dirty.

The Public-Interest factors at 21 U.S.C. § 823(e)–(g) are the canonical denial grounds: maintenance of effective controls against diversion, compliance with state and local laws, prior conviction record of officers, past experience in distributing or dispensing, public health and safety record, and Single Convention compliance. Operators with state-level warning letters, unresolved METRC discrepancies, lab-shopping histories, or unclosed CAPAs from state inspections are exposed — even if the state ultimately took no formal enforcement action.

Most state-cannabis operators have never written a Public-Interest defense memo. Most have not reconciled their METRC genealogy against COA pedigree against transport manifest against batch records to confirm the data tells a consistent story. The pain is that this work is conceptually familiar (it's diversion control), but the artifacts the federal regulator will expect are not produced in the normal course of state-cannabis operations.

The Federal Pathway Primer's Section 6 lays out a § 823 factor-by-factor framework for the defense memo. Worth getting the memo drafted before you submit, not after DEA asks for it.

Pain Point #3 — The Single Convention Nominal-Price Buy/Sell-Back

This is the most operationally novel piece of the new framework, and the one most manufacturers don't yet have SOPs for.

Article 23 of the 1961 Single Convention on Narcotic Drugs requires the U.S. government to operate as the exclusive purchaser of cannabis production within its borders. DEA satisfies this obligation through 21 CFR Part 1318 — but § 1301.13(k)(6) carves state-medical operators out of Part 1318 and re-imposes a parallel nominal-price purchase-and-resale obligation directly on state-medical manufacturers. Net effect: the buy/sell-back applies to every registered state-medical manufacturer, via § 1301.13(k)(6) rather than Part 1318.

The four-step workflow the manufacturer must build SOPs for:

Establish a nominal price for each crop;
DEA "purchases" the crop at that price;
DEA "resells" the crop back to the same manufacturer (or a related/subsidiary entity) at that same price plus an administrative fee calculated under 21 CFR § 1318.06(a);
Until the transaction closes, the crop must be stored in a facility to which DEA maintains physical access, with inspection-on-demand rights.

It is a paper transaction in mechanism, but it requires real artifacts: a nominal-price determination methodology (defensible batch-to-batch — too low risks IRS or DEA sham-transaction challenge; too high risks inventory-step-up tax liability), a batch-record SOP that triggers the buy/sell-back at harvest logging, storage-area mapping identifying the DEA-accessible facility, and facility-access protocols for DEA inspectors covering badging, escort, and after-hours response.

Open guidance gap: § 1301.13(k)(6)(A) cross-references § 1318.06(a) for the administrative fee calculation, but neither the rule nor DEA implementation materials specify the fee amount or methodology. Build SOPs that can absorb either a flat-per-harvest or percentage-of-nominal-price structure until DEA issues guidance.

Pain Point #4 — Schedule III Federal Operational Overlay

Even where the rule allows state-law packaging, labeling, disposal, and physical security to substitute for federal requirements, several federal minimums apply with no state substitute. State-cannabis operators have not been building to these.

The federal minimums that survive any state substitution:

21 U.S.C. § 825(c) statutory warning label added to every container's label
Initial inventory of all stocks of controlled substances on hand on the date federally registered activity begins, plus biennial inventory every two years thereafter (21 U.S.C. § 827)
Theft and loss reporting via DEA Form 106, parallel to any state-level reporting
Order forms governing inter-registrant transfers
Disposal under 21 CFR Part 1317 for FDA-approved drug products (state-law disposal substitution applies only to non-FDA-approved state-medical product)
Recordkeeping and reporting that leverages state systems where permissible, but must be federally retrievable during a § 1301.71 DEA inspection — i.e., on-demand, not after a 30-day vendor data request

The pain here is sequencing. The federal overlay can be built in parallel with the registration sprint — but most operators discover the overlay after they file, and end up retroactively bolting the warning label onto label artwork that was already printed, scrambling to schedule the initial inventory event, and writing the Form 106 workflow under deadline pressure when their first theft/loss event happens.

Pain Point #5 — Part 211 Applicability for FDA-Approved and IND-Track Operators

This is the cleanest pharma-GMP question in the new regime, and the one that drives the longest-tail consulting engagements.

21 CFR Part 211 (cGMP for finished pharmaceuticals) does not automatically apply to state-licensed medical marijuana. State medical product remains regulated by state cannabis law — but is now a Schedule III controlled substance subject to DEA's Part 1300-series.

Part 211 does apply where:

The product is an FDA-approved drug product containing marijuana (currently a narrow set, but growing through the IND/NDA pathway)
The operator is pursuing IND (21 CFR Part 312) or NDA / ANDA / 505(b)(2) (21 CFR Part 314) filings
The operator is supplying clinical trial material (CTM) to DEA-registered researchers under the new § 1301.13(k) research carve-out — § 312.23 controls apply to CTM regardless of who supplies it
The operator is positioning for EU pharmacy export (which additionally requires EU-GMP Part II + Annex 7 compliance) or pharma partnership / contract manufacturing with an FDA-regulated sponsor

For operators in any of these lanes, the right move is to start the Part 211 build now rather than later — not because state-medical operations are about to require it (they aren't), but because operators who try to add IND/NDA-grade infrastructure to a steady-state state-cannabis operation after the fact end up rebuilding master records, re-validating processes, re-qualifying suppliers, and re-training operators. The cost asymmetry is large.

See the companion piece Build Once, Build to the Highest Bar: The Integrated GMP Stack for Pharmaceutical-Pathway Cannabis for the integrated ICH Q10 / EU-GMP / Part 211 architecture and the strategic argument against three siloed builds.

Pain Point #6 — 280E Tax Posture and Production Segregation

The rule itself notes that qualifying state-medical licensees are no longer subject to IRC § 280E, which applies only to businesses engaged in trafficking in Schedule I or II controlled substances. Treasury and IRS jointly announced on April 23, 2026 that they will issue guidance — including how 280E is apportioned for operators with mixed medical and adult-use activities.

While not a GMP service in itself, this drives a chart-of-accounts and production-segregation problem that touches manufacturing operations directly. To defensibly apportion costs and revenue between medical (no 280E) and adult-use (still 280E) lines, the underlying production data has to support the apportionment:

Plant lots, batch numbers, METRC tag genealogy, processing equipment, packaging components, and disposal streams must be designated as medical or adult-use from cultivation onward
Internal transfers between medical and adult-use inventory create federal-trafficking exposure (medical → adult-use becomes a sale of Schedule III to a non-registered destination; adult-use → medical creates Schedule I material in a federally registered system)
The chart of accounts has to support cost allocation by line, not just aggregate operations
Operators in states that designate medical vs. adult-use only at point of sale (Arizona is the canonical example) likely cannot demonstrate that any specific cultivation lot is "subject to a state medical marijuana license" at the time of cultivation — and may be structurally ineligible for § 1301.13(k) registration until the state regulatory model bifurcates upstream

Caution on retroactive 280E claims. Treasury's language is "encourage" not "mandate." It is not a safe harbor and creates no enforceable right to refund. Practitioners should specifically caution clients against filing amended returns for 2022-2025 solely on the basis of the April 2026 order until Treasury issues formal transitional guidance or a court ruling supports the position. Coordinate with cannabis tax counsel before any retroactive-claim activity.

Pain Point #7 — International Export Readiness

The amendment to 21 CFR § 1312.30 adds the three new state-medical categories to the list of nonnarcotic Schedule III–V controlled substances subject to import/export permit requirements. In plain terms: U.S. state-licensed medical marijuana is for the first time importable and exportable under DEA permit.

The U.S. side of the transaction is the easy half. The destination-country side is the operationally heavy half:

EU pharmacy markets (Germany, UK, Czechia, Poland, Italy, etc.) require EU-GMP Part II + Annex 7 for the manufacturer and Annex 16 Qualified Person (QP) certification for batch release
Israel requires IMC-GMP (Israeli Medical Cannabis Agency standard, broadly aligned with EU-GMP Part II with IMC-specific overlays)
Canada (via distribution partnership) requires Health Canada DEL plus Good Production Practices
Australia operates under TGA with reference to PIC/S PE 009
Brazil operates under the ANVISA medical cannabis framework

A § 1301.13(k)-registered operator holding a DEA export permit for a specific shipment still cannot lawfully sell into Germany unless the manufacturing site is qualified to EU-GMP. The U.S. permit is necessary but not sufficient.

There's also a structural limitation that took most operators by surprise: every export shipment must originate from a single state-licensed operation. There is no national export hub model under this rule. An MSO with operations in five states pursuing export operates five independent export pathways — five state licenses, five § 1301.13(k) registrations, five EU-GMP qualifications, five permit streams.

Caveats and watch-items

Several items worth flagging to set realistic expectations and avoid over-promising as regulatory implementation matures:

The order is litigation-exposed. Smart Approaches to Marijuana (SAM) has announced an Administrative Procedure Act challenge arguing the § 811(d)(1) treaty pathway was improperly invoked. The order contains an express severability provision, signaling DOJ anticipates partial challenges. A Congressional Review Act resolution remains possible. Build flexibility into any compliance investment scoped against the new regime.
Treasury and IRS guidance is not yet issued. The 280E-removal narrative is correct in principle but the apportionment rules for dual operators are TBD.
The prescription-vs-recommendation tension is unresolved. Schedule III drugs require valid prescriptions under the CSA; state medical programs operate on physician recommendations. The order does not directly resolve this; expect future DEA or state-level rule activity.
Interstate commerce remains illegal, even between two § 1301.13(k)-registered medical operators in different states. The rule does not open the interstate medical lane. Only international import/export under DEA permit is newly available.
Banking is largely unchanged. SBA loans and most federal small-business programs still exclude plant-touching cannabis regardless of Schedule III status. SAFER Banking remains stalled in Congress.
Federal employment drug-testing rules (DOT, federal contractor) are unchanged by the order. Separate regulatory action is required.
Synthetically derived THC (delta-8, delta-10, synthetic delta-9) is explicitly excluded from the rescheduling.
Hemp is unaffected by the April 2026 order — but the federal hemp definition shifts to "total THC including THCA" on November 12, 2026 under November 2025 legislation. Operators with hemp operations or hemp-derived intermediates in the supply chain face a parallel reclassification risk requiring its own remediation plan.

What to do in the next 60, 180, and 365 days

A pragmatic sequencing question every C-suite is asking. The short answer:

Next 60 days (now to early July): File the DEA registration. Draft the Public-Interest defense memo. Build the buy/sell-back SOP and storage-access protocol. If you are dual-licensed, audit your production segregation against the medical/adult-use apportionment requirement before Treasury guidance crystallizes.

Next 180 days (through Q4 2026): Land the Schedule III federal overlay — § 825(c) labeling, initial inventory event, biennial inventory schedule, Form 106 workflow, federally-retrievable records architecture. If you are pursuing EU export, IND/NDA, or pharma partnership, begin the gap assessment against the relevant downstream standard (EU-GMP Part II + Annex 7; 21 CFR Part 211).

Next 365 days (through mid-2027): For state-medical-only operators, mature the federal overlay into steady-state operations and prepare for the first § 1301.71 DEA inspection. For pharma-pathway operators, complete the integrated GMP build — the cost of building Part 211 + EU-GMP at the highest common bar in one pass is materially lower than building them sequentially.

How Intrepid Scientific engages on these

The pains above map onto specific scoped engagements. The primary entry point for operators in the federal-pathway window is the GACP + GMP Gap Assessment aligned to Schedule III — a scoped Stage 1 assessment that maps cultivation and manufacturing practices against the standards required by your chosen downstream lane (state-medical plus § 1301.13(k) overlay, EU GMP / Annex 7 export, IND/NDA, CTM supply, or pharma partnership). It delivers gap findings against specific clauses of the target standard, a sequenced remediation roadmap, a CAPA register, and a binding Stage 2 scope recommendation for any of the candidate follow-on engagements (DEA registration support, Design Qualification + commissioning, integrated PQS build, EU GMP bridge, expert witness support, or ongoing retainer).

For operators who are specifically narrow on the DEA registration question and already have a clean GMP posture, the Federal Pathway Readiness Diagnostic is a tighter $4,000 fixed-fee engagement scoped to § 1301.13(k) readiness alone.

Both are quote-and-scope engagements with cofounder-level delivery and the methodology principles we use across every engagement: phased and decision-gated, mutual exit rights at the end of Stage 1, no junior backfill, the senior names on the wall delivering the work themselves.

Talk to us about a gap assessment →

Read the strategic overview — The Pharmaceutical Era →

Get the 60-Day Federal Pathway Primer →

Read the integrated GMP stack — Build Once, Build to the Highest Bar →

About the Author

Andrew Samann is a Cofounder of Intrepid Scientific. Recognized as a Processing Pro on The Cannabis Scientist's Power List for 2021 and 2022, Andrew has led over 100 GMP and quality-system engagements across North America, South America, and the European Union — including international compliance work against FDA, EU GMP, EMA, Australian TGO, and ICH guidelines. He led the ASTM D37.02 Quality Management Systems Subcommittee for Cannabis, has certified multiple Canadian cannabis Licensed Producers, and is also Founder & CEO of Orion GMP Solutions.

About Intrepid Scientific

Intrepid Scientific is an independent scientific consulting firm offering ISO/IEC 17025 lab accreditation readiness, GMP and cGMP compliance, analytical method development and validation, microbiology and environmental monitoring, expert witness, and Federal Pathway / Schedule III advisory across cannabis, hemp, food and beverage, pharmaceutical, and dietary-supplement industries. Senior scientists. Direct engagement.

Cofounders: Andrew Samann; Kate Evans, PhD; Tess Eidem, PhD; Julie Kowalski, PhD.

Learn more at intrepidscientific.com.